Google Translate Limitations Disclaimer

The electronic translation service on the brainXchange website is hosted by Google Translate, an external translation service. The brainXchange does not guarantee or warrant the reliability, accuracy or completeness of any translated information. The basic translation goal is to capture the general information of the original English website content. If any questions arise related to the accuracy of the information contained in the translated website, please refer to the English version of the website.

Home > Events > Archived Webinars & Events > 2020 > An update on Lewy body spectrum disorders

An update on Lewy body spectrum disorders

Event Date: Jun 17, 2020

Related Resources l Recording

Using a case-based approach, we will review the following:

To compare the clinical features of dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD), with a focus on diagnostic issues
To compare the cognitive profile of DLB, PDD and Alzheimer’s disease
To understand the underlying brain changes of DLB and PDD
To understand the multi-factorial approach to management of DLB and PDD

This integrated KTE webinar event is brought to you by brainXchange in partnership with the Alzheimer Society of Canada and the Canadian Consortium of Neurodegeneration in Aging (CCNA).

Related Documents:

Lewy Body dementia, Alzheimer Society of Canada

Presenter(s):

Mario Masellis, MSc, MD, PhD, FRCPC
Clinician Scientist and Associate Professor, Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto

Dr. Mario Masellis obtained his MSc in Pharmacology from the University of Toronto in 1997, completed his medical training at the University of Toronto in 2001 and obtained his board certification (FRCP Canada) in Neurology since 2006. He has completed a clinical research fellowship in Cognitive & Movement Disorders Neurology in 2008 and obtained a PhD in Clinical Neurosciences in 2012. His clinical expertise is in the diagnosis and management of both Alzheimer’s and non-Alzheimer’s dementias, including Lewy body disorders, frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome. His research focuses on how genomic factors impact neuroimaging and cognitive phenotypes, and response to drugs in neurodegenerative diseases.